Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

A sophisticated, single-file web application that enables users to write, execute, and manage Python code directly within their web browser. Built on top of Pyodide - a WebAssembly-compiled Python ...

A sophisticated, single-file web application that enables users to write, execute, and manage Python code directly within their web browser. Built on top of Pyodide - a WebAssembly-compiled Python ...

Judge says Greenpeace must pay $345 million in pipeline lawsuit, cutting jury amount nearly in half Republican senators strongly rebuke Trump's NATO troop withdrawal Dodgers make lineup changes for ...

In a significant move for Replimune Group, Inc. (ticker: REPL), analyst Robert Burns of HC Wainwright & Co. upgraded the company to a “Buy” on October 27, 2025, setting a price target of $12. This ...

During this cooking tutorial, this woman tries to show how to cook chestnuts. She forgets that overheated chestnuts are vulnerable to explosion, and the chestnut winds up exploding. BBC leaders resign ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...